The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor
immunity by generating type I interferons. In recent decades, we have witnessed that …

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have
been effective in only a small subset of patients and a principal mechanism underlying …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) are essential
components of the innate immune sensors to cytosolic DNA and elicit type I interferon (IFN) …

Cancer immunotherapy modulates and leverages the host immune system to treat cancer.
The past decade has witnessed historical advancement of cancer immunotherapy. A myriad …

Abstract STING (Stimulator of Interferon Genes) agonists have emerged as promising agents
in the field of cancer immunotherapy, owing to their excellent capacity to activate the innate …

Since cyclic guanosine monophosphate‐adenosine monophosphate synthase (cGAS)–
stimulator of interferon genes (STING) signaling pathway was discovered in 2013, great …

Personalized cancer vaccines (PCVs) are reinvigorating vaccine strategies in cancer
immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV …

In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …

As prophylactic vaccine adjuvants for infectious diseases, cyclic dinucleotides (CDNs)
induce safe, potent, long-lasting humoral and cellular memory responses in the systemic …